RTU 1096

Drug Profile

RTU 1096

Alternative Names: RTU-1096; VAP-1 inhibitors - Sucampo Pharmaceuticals

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator R-Tech Ueno
  • Developer Hokkaido University; Kyushu University; Sucampo Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Cataracts; Contact dermatitis; Diabetic macular oedema; Diabetic neuropathies; Diabetic retinopathy; Psoriasis

Most Recent Events

  • 09 Nov 2016 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in Japan (PO) before November 2016
  • 09 Nov 2016 Discontinued - Phase-I for Diabetic macular oedema in Japan (PO) before November 2016
  • 09 Nov 2016 Discontinued - Phase-I for Diabetic retinopathy in Japan (PO) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top